DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

ProductUpdated on 22 April 2026

A probiotic to improve udder health

Sven ARNOUTS

Business Development Manager at Ghent University - provaxs

Merelbeke, Belgium

About

Developed from a selected Staphylococcus chromogenes strain originating from bovine milk our strain demonstrates in vitro inhibitory activity against major mastitis pathogens (e.g. Staphylococcus aureus—including methicillin-resistant strains—Escherichia coli, Streptococcus uberis), pro-immune modulation, and its ability to colonize the udder environment.

Designed for use in dairy cattle (potentially goats and sheep) our probiotic supports a balanced mammary gland microbiota, reduces the risk of intramammary infections, and promotes faster recovery following clinical mastitis cases. By enhancing udder health, the product contributes to (indirect) increase in milk production, animal welfare, and reduced reliance on antimicrobial treatments.

In vivo proof of concept in dairy cattle

18 cows were included in the study and treatments (inoculated with the probiotic or non-inoculated) were divided over individual udder quarters (72 quarters). The inoculated quarters not only showed less incidence of sub-clinical and clinical mastitis, the most pronounced/valuable effect was the increased milk production in the inoculated quarters: over the 305-day period of the study an extra gain of 141 liter milk per inoculated quarter (thus 564 liter per cow) was observed. Moreover, the recovery of milk production after an incidence of clinical mastitis was remarkably better in inoculated quarters: a loss of 0,8 liter per quarter on average on the day of clinical mastitis versus 8,5 liter per quarter in non-inoculated quarters.

Partnering

We are reaching out to partners who are interested in development and marketing of our novel probiotic.

Looking for

  • Commercial Partner
  • Strategic Partner
  • Industry Partner
  • Technology Partner
  • Licensing Partner

Applies to

  • Animal Health Biotechnology
  • Veterinary Therapeutics
  • Livestock Farming
  • Antimicrobial Resistance Solutions
  • Sustainable Livestock Health

Organisation

Ghent University - provaxs

Merelbeke, Belgium

Similar opportunities

  • Product

    A biological to treat pyoderma

    • Investor
    • Industry Partner
    • Strategic Partner
    • Licensing Partner
    • Technology Partner
    • Manufacturing Partner
    • Veterinary Therapeutics
    • Animal Health Biotechnology
    • Antimicrobial Resistance Solutions

    Sven ARNOUTS

    Business Development Manager at Ghent University - provaxs

    Merelbeke, Belgium

  • Expertise

    Accelerating Animal Health R&D through Biological Intelligence

    • Diagnostics Development
    • AI & Predictive Analytics
    • Biotechnology & Life Sciences
    • Digital Health & Data Science
    • Clinical & Veterinary Research
    • Agritech & Precision Livestock
    • Translational & Applied Research
    • Epidemiology & Infectious Disease

    Alexander Koch

    Scientific engagement manager at BioLizard

    Brussels, Belgium

  • Project cooperation

    Virbac Animal Health

    • Animal Health
    • Animal Welfare
    • Licensing Partner
    • Distribution Partner
    • Vaccines & Immunology
    • Digital Animal Health
    • Veterinary Diagnostics
    • Antimicrobial Resistance
    • Commercialisation Partner
    • Precision Livestock Farming
    • Biotechnology & Life Sciences
    • Sustainable Livestock Systems
    • Technology Development Partner

    Jean-Baptiste RASCLE

    Business Development Manager at VIRBAC

    Carros, France